Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
International Journal of Hepatology · 2018 · 2018 · 1-13
DOI: 10.1155/2018/5253623 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Hepatology, 2018. Verfasst von Pajaree Sriuttha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain. Aim of the Review . To systematically review published literature on randomized, controlled trials that assessed the risk of clinically significant hepatotoxicity associated with NSAIDs.
Methods
Searches of bibliographic databases EMBASE, PubMed, and the Cochrane Library were conducted up to July 30, 2016, to identify randomized controlled trials of ibuprofen, naproxen, diclofenac, piroxicam, meloxicam, mefenamic acid, indomethacin, celecoxib, and etoricoxib in adults with any disease that provide information on hepatotoxicity outcomes.
Results
Among the 698 studies, 18 studies met the selection criteria. However, only 8 studies regarding three NSAIDs (celecoxib, etoricoxib, and diclofenac) demonstrated clinically significant hepatotoxic evidence based on hepatotoxicity justification criteria. Of all the hepatotoxicity events found from the above-mentioned three NSAIDs, diclofenac had the highest proportion, which ranged from 0.015 to 4.3 (×10 −2 ), followed by celecoxib, which ranged from 0.13 to 0.38 (×10 −2 ), and etoricoxib, which ranged from 0.005 to 0.930 (×10 −2 ).
Conclusion
Diclofenac had higher rates of hepatotoxic evidence compared to other NSAIDs. Hepatotoxic evidence is mostly demonstrated as aminotransferase elevation, while liver-related hospitalization or discontinuation was very low.
Autor:innen und Institutionen
- Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Pajaree Sriuttha
Zitieren
APA
Sriuttha, P., Sirichanchuen, B., & Permsuwan, U. (2018). Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International Journal of Hepatology, 2018, 1-13. https://doi.org/10.1155/2018/5253623
Vancouver
Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International Journal of Hepatology. 2018;2018:1-13. doi:10.1155/2018/5253623
BibTeX
@article{Sriuttha2018,
author = {Sriuttha, Pajaree and Sirichanchuen, Buntitabhon and Permsuwan, Unchalee},
title = {Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials},
journal = {International Journal of Hepatology},
year = {2018},
volume = {2018},
pages = {1--13},
doi = {10.1155/2018/5253623}
}
EUVIMED